Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
BAN ORL 24 is a novel, potent and selective NOP (nociceptin/orphanin FQ (N/OFQ) peptide receptor) receptor antagonist with IC50 values of 0.27, 2500, 6700 and > 10000 nM for NOP, κ-, μ- and δ-receptors respectively. Compound 24 (BAN ORL 24) did not change the way classical opioid receptor agonists worked even at concentrations of up to 1 microM. Lastly, in vivo, Compound 24 at 10 mg/kg countered the pronociceptive and antinociceptive effects of 1 nmol N/OFQ administered spinally and supraspinally, respectively, in the mouse tail withdrawal assay. Compound 24 had no effect on the intrathecal injection of 3 nmol endomorphin-1's antinociceptive action under the same experimental conditions. Compound 24 is a pure, competitive, and extremely powerful non-peptide NOP receptor selective antagonist, as the current study has shown.
ln Vitro |
BAN ORL 24 has NOR and MOR (opioid receptor subtype) antagonists with IC50 values of 50 μM and 0.224 μM respectively [2].
|
---|---|
ln Vivo |
BAN ORL 24 (10 mg/kg; intravenously) attenuates the duration of BPRIM97 thermal analgesia [3]. Animal model: C57BL/6 mice [3] Dose: 10 mg/kg Administration dose: 10 mg/kg; iv results: Inhibited BPRIM97-induced analgesia 90 minutes after injection. BPR1M97-induced analgesia was not attenuated in the tail-clip test after 30 minutes.
|
References |
Molecular Formula |
C27H37CL2N3O2
|
---|---|
Molecular Weight |
506.507585287094
|
Exact Mass |
505.23
|
Elemental Analysis |
C, 64.03; H, 7.36; Cl, 14.00; N, 8.30; O, 6.32
|
CAS # |
1401463-54-4
|
Related CAS # |
BAN ORL 24 free base; 475150-69-7
|
Appearance |
Solid powder
|
SMILES |
C1C[C@@H](N(C1)CC2=CC=CC=C2)C(=O)NCCCN3CCC4(CC3)C5=CC=CC=C5CO4.Cl.Cl
|
InChi Key |
NEEVITHVDIQNJY-KHZPMNTOSA-N
|
InChi Code |
InChI=1S/C27H35N3O2.2ClH/c31-26(25-12-6-17-30(25)20-22-8-2-1-3-9-22)28-15-7-16-29-18-13-27(14-19-29)24-11-5-4-10-23(24)21-32-27;;/h1-5,8-11,25H,6-7,12-21H2,(H,28,31);2*1H/t25-;;/m1../s1
|
Chemical Name |
(2R)-1-benzyl-N-(3-spiro[1H-2-benzofuran-3,4'-piperidine]-1'-ylpropyl)pyrrolidine-2-carboxamide;dihydrochloride
|
Synonyms |
BAN-ORL-24 HCl; BAN-ORL-24 dihydrochloride; BAN-ORL24; BAN-ORL 24; BANORL-24; BANORL 24; BANORL24; BAN ORL 24
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~200 mg/mL (~394.86 mM)
H2O : ~100 mg/mL (~197.43 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (9.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (9.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (9.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (197.43 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9743 mL | 9.8715 mL | 19.7429 mL | |
5 mM | 0.3949 mL | 1.9743 mL | 3.9486 mL | |
10 mM | 0.1974 mL | 0.9871 mL | 1.9743 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.